Misplaced Pages

Elcatonin: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively
Page 1
Page 2
← Previous editContent deleted Content addedVisualWikitext
Revision as of 18:28, 8 August 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per [[Misplaced Pages:WikiProject Chemicals/Chem← Previous edit Latest revision as of 03:10, 11 December 2024 edit undoSmarbi (talk | contribs)494 editsNo edit summary 
(15 intermediate revisions by 14 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{drugbox
{{Drugbox
| verifiedrevid = 443720432
| Watchedfields = changed
| IUPAC_name =
| verifiedrevid = 443721979
| image = Elcatonin.png
| IUPAC_name =
| CAS_number = 60731-46-6
| image = Elcatonin.png
| ATC_prefix = H05

| ATC_suffix = BA04
<!--Clinical data-->
| tradename =
| Drugs.com = {{drugs.com|international|elcatonin}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =

<!--Identifiers-->
| CAS_number = 60731-46-6
| ATC_prefix = H05
| ATC_suffix = BA04
| PubChem = 16129700
| ChemSpiderID = 17294280
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| UNII_Ref = {{fdacite|correct|FDA}} | UNII_Ref = {{fdacite|correct|FDA}}
| UNII = W0CMS474JK | UNII = W0CMS474JK
| KEGG = D03287
| PubChem = 16129700

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
<!--Chemical data-->
| DrugBank =
| chemical_formula = | chemical_formula =
| C=148|H=244|N=42|O=47 | C=148 | H=244 | N=42 | O=47
| smiles = /N=C(/N)\NCCC(C(=O)N((C)O)C(=O)N(CC(=O)O)C(=O)N(C(C)C)C(=O)NCC(=O)N(C)C(=O)NCC(=O)N((C)O)C(=O)N1CCC1C(=O)N)NC(=O)2CCCN2C(=O)(Cc3ccc(cc3)O)NC(=O)((C)O)NC(=O)(CCC(=O)N)NC(=O)(CC(C)C)NC(=O)(CCCCN)NC(=O)(Cc4ccn4)NC(=O)(CC(C)C)NC(=O)(CCC(=O)O)NC(=O)(CCC(=O)N)NC(=O)(CO)NC(=O)(CC(C)C)NC(=O)(CCCCN)NC(=O)CNC(=O)(CC(C)C)NC(=O)(C(C)C)NC(=O)5CCCCCC(=O)N(C(=O)N(C(=O)N(C(=O)N(C(=O)N(C(=O)N5)(C)O)CO)CC(C)C)CC(=O)N)CO
| molecular_weight = 3363.78 g/mol
| StdInChI=1S/C148H244N42O47/c1-69(2)52-91(178-142(232)115(75(13)14)185-127(217)86-30-21-20-22-36-108(202)165-100(65-191)137(227)177-97(59-107(153)201)135(225)175-95(56-73(9)10)133(223)182-102(67-193)139(229)188-116(77(16)194)143(233)171-86)122(212)160-63-110(204)164-84(31-23-25-47-149)123(213)172-94(55-72(7)8)132(222)181-101(66-192)138(228)169-88(41-44-105(151)199)125(215)167-90(43-46-112(206)207)126(216)174-93(54-71(5)6)131(221)176-96(58-82-61-157-68-162-82)134(224)166-85(32-24-26-48-150)124(214)173-92(53-70(3)4)130(220)168-89(42-45-106(152)200)129(219)187-118(79(18)196)145(235)180-99(57-81-37-39-83(198)40-38-81)146(236)190-51-29-35-104(190)140(230)170-87(33-27-49-158-148(155)156)128(218)186-117(78(17)195)144(234)179-98(60-113(208)209)136(226)184-114(74(11)12)141(231)161-62-109(203)163-76(15)121(211)159-64-111(205)183-119(80(19)197)147(237)189-50-28-34-103(189)120(154)210/h37-40,61,68-80,84-104,114-119,191-198H,20-36,41-60,62-67,149-150H2,1-19H3,(H2,151,199)(H2,152,200)(H2,153,201)(H2,154,210)(H,157,162)(H,159,211)(H,160,212)(H,161,231)(H,163,203)(H,164,204)(H,165,202)(H,166,224)(H,167,215)(H,168,220)(H,169,228)(H,170,230)(H,171,233)(H,172,213)(H,173,214)(H,174,216)(H,175,225)(H,176,221)(H,177,227)(H,178,232)(H,179,234)(H,180,235)(H,181,222)(H,182,223)(H,183,205)(H,184,226)(H,185,217)(H,186,218)(H,187,219)(H,188,229)(H,206,207)(H,208,209)(H4,155,156,158)/t76-,77+,78+,79+,80+,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,114-,115-,116-,117-,118-,119-/m0/s1
| bioavailability =
| StdInChIKey = DDPFHDCZUJFNAT-PZPWKVFESA-N
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category=
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =
| routes_of_administration =
}} }}

]
'''Elcatonin''' is a ] derivative used as an anti-] agent. '''Elcatonin''' is a ] derivative used as an anti-] agent.


Elcatonin is a Calcitonin derivative which is transformed from eel's calcitonin by changing the S-S bond into the stable C-N bond. It inhibits the absorption and autolysis of bones, thus leads to blood calcium descending. In addition, it inhibits the bone salts dissolving and transferring and promotes the excretion of calcium and phosphorus in urine. Meanwhile, it inhibits renal tubules reabsorbing calcium, phosphorus and sodium and keeps blood calcium at normal level. It is mainly used for remitting or eliminating the pain caused by Osteoporosis. It is transformed from eel's calcitonin by changing the S-S bond into a stable C-N bond. It inhibits the absorption and ] of bones and thus leads to lowering of blood calcium. It inhibits bone salts from dissolving and transferring and promotes the excretion of calcium and phosphorus in the urine. It inhibits renal tubules from reabsorbing calcium, phosphorus and sodium and keeps blood calcium at a normal level.{{fact|date=April 2019}} It is mainly used for remitting or eliminating pain caused by ].<ref>{{cite journal | vauthors = Yoh K, Uzawa T, Orito T, Tanaka K | title = Improvement of Quality of Life (QOL) in Osteoporotic Patients by Elcatonin Treatment: A Trial Taking the Participants' Preference into Account | journal = Japanese Clinical Medicine | volume = 3 | pages = 9–14 | year = 2012 | pmid = 23946680 | pmc = 3738553 | doi = 10.4137/JCM.S8291 }}</ref><ref>{{cite journal | vauthors = Tanaka S, Yoshida A, Kono S, Oguma T, Hasegawa K, Ito M | s2cid = 21904979 | title = Effectiveness of elcatonin for alleviating pain and inhibiting bone resorption in patients with osteoporotic vertebral fractures | journal = Journal of Bone and Mineral Metabolism | volume = 35 | issue = 5 | pages = 544–553 | date = September 2017 | pmid = 27830386 | doi = 10.1007/s00774-016-0791-6 }}</ref>

== References ==
{{reflist}}


{{Calcium homeostasis}} {{Calcium homeostasis}}



] ]



{{systemic-hormonal-drug-stub}} {{systemic-hormonal-drug-stub}}
Elcatonin: Difference between revisions Add topic